Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seragon Pharmaceuticals IncfiledCriticalSeragon Pharmaceuticals Inc
Publication of UY35622ApublicationCriticalpatent/UY35622A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Steroid Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Compuestos que son moduladores de los receptores de estrógeno. Composiciones farmacéuticas y medicamentos que los comprenden. Métodos para usarlos, solos o en combinación con otros compuestos, en el tratamiento de aquellas enfermedades y aquellas afecciones que están mediadas por los receptores de estrógeno o que dependen de los receptores de estrógeno.Compounds that are estrogen receptor modulators. Pharmaceutical compositions and medications that comprise them. Methods for using them, alone or in combination with other compounds, in the treatment of those diseases and conditions that are mediated by estrogen receptors or that depend on estrogen receptors.
UY35622A2013-06-192014-06-18
MODULATORS OF ESTROGEN RECEIVERS AND THEIR USES
UY35622A
(en)
Sting modulating cyclic dinucleotides; Composition and pharmaceutical combination that includes them and their use for the treatment of diseases such as inflammation, allergic and autoimmune diseases, infectious diseases and cancer.
Compounds derived from pyrrole, pyridine or piperidine substituted with heterocycles, modulators of the protein-coupled receptor g 40 (gpr40); pharmaceutical composition comprising them; and its use for the treatment of diseases such as diabetes, retinopathy, neuropathy, atherosclerosis, obesity and hypertension.